

**The Collaboration for TB Vaccine Discovery (CTVD) Launch Meeting  
Bill & Melinda Gates Foundation, Seattle, WA  
July 9<sup>th</sup> to 10<sup>th</sup>, 2015**

*The CTVD was launched to foster innovation, cooperation and collaboration in the up-stream TB vaccine discovery space. We believe this effort will accelerate development of a more effective vaccine against TB.*



### Attendees

The CTVD launch brought together a diverse group of stakeholders in TB vaccine discovery and development. *Thank you* to the following representatives from academia, independent research institutes, industry and funding organizations:

Alan Aderem (CIDR)	Peggy Johnston (BMGF)	Bob Ryall (Sanofi Pasteur)
Peter Andersen (SSI)	Gilla Kaplan (BMGF)	Nina Russell (BMGF)
Dan Barber (NIAID)	Chris Karp (BMGF)	Melvin Sanicas (BMGF)
Sam Behar (UMass)	Anne Kasmar (BMGF)	Lew Scharger (Aeras)
Barry Bloom (HSPH)	Stefan Kaufmann (MPIIB)	Tom Scriba (UCT)
Aurelio Bonavia (Aeras)	Paul-Henri Lambert (UGeneve)	Bob Seder (NIAID)
Rhea Coler (IDRI)	Al Leslie (K-RITH)	Laura Shackelton (BMGF)
Andrea Cooper (Trudeau)	Dave Lewinsohn (OHSU)	Sally Sharpe (PHE)
Eva Chung (FHCRC)	Karen Makar (BMGF, GH-VAP)	Jacqui Shea (Aeras)
Nick Drager (TBVI)	Carlos Martin (UZaragoza)	Alex Sigal (K-RITH)
Katrin Eichelberg (NIAID)	Julie McElrath (FHCRC)	Christine Sizemore (NIAID)
JoAnne Flynn (UPitt)	Helen McShane (Oxford)	Steffen Stenger (UUIIm)
Sarah Fortune (HSPH)	Branch Moody (B&WH)	Lynda Stuart (BMGF)
Chris Gast (FHCRC)	Olivier Neyrolles (IPSB)	Frank Verreck (BPRC)
Ann Ginsberg (Aeras)	Ian Orme (CSU)	Gerald Voss (GSK)
Raphael Gottardo (FHCRC)	Tom Ottenhoff (ULeiden)	Barry Walker (Aeras)
Willem Hanekom (BMGF)	Louis Picker (OHSU)	Chris Wilson (BMGF)
Tom Hawn (UW)	Ann Rawkins (PHE)	Douglas Young (Imperial)
Dan Hoft (SLU)	Mario Roederer (NIAID)	Dan Zak (CIDR)

## Key messages

- The CTVD is modeled after the Collaboration for AIDS Vaccine Discovery (CAVD), to a large extent. CAVD was launched in 2006 and has focused on diversifying the vaccine pipeline, standardizing lab assays and reagents and increasing access to tools and services, primarily. Early data sharing is an essential component. The spirit of CAVD reflects balance between productive competition and collaboration.
- CTVD aims to:
  - o Facilitate discussion and action among stakeholders involved in TB vaccine discovery and early product development
  - o Enable early sharing of scientific data, and sharing of research materials
  - o Establish rigorous standards for experimental approaches and data analysis
  - o Provide access to best in class services to facilitate TB vaccine discovery and early product development
  - o Promote lab exchanges, scientific visits, and technology transfer
  - o Cultivate the next generation of TB vaccine investigators, as well as attract established investigators into the field
  - o Be a vehicle for communication of best practices and common ideas
  - o Align with complementary global organizations that address other aspects of TB vaccine development
  - o Advocate for TB vaccine resource mobilization, using the voice of a community united behind a common goal
- Individual “research communities” will be established to:
  - o Wrestle with big problems in a collaborative manner
  - o Promote innovation in these areas
  - o Identify priorities for focus
  - o Design or advise on approaches to address identified priorities

## Some highlights from the discussion...

- The need to learn from CAVD. In CTVD, introduce what has worked well.
- We wish to focus on areas for which collaboration within CTVD is essential; we do not wish to replicate other valuable activities in the TB vaccine field.
- CTVD may be the critical link between the basic and vaccine development. We need to bring product development to the table early!
- Data sharing is important; data quality is essential. We have to find a way to share data in an accessible manner. Sharing of negative data will also be valuable.
- The community would benefit from shared data, analytical tools, materials, reagents, and assays. Greater standardization of NHP and clinical assay procedures was a recurring theme at the meeting.
- There was a consensus that a capacity building / exchange program (*lab visits to learn techniques and exchange ideas*) between CTVD members would be valuable.
- Initially, no specific funding would be assigned to CTVD; however, many individual grants in the upstream TB vaccine space are funded by the foundation, directly or indirectly. We would like to see CTVD guide further funding action.
- CTVD research communities would be open to all; CTVD services would be accessible only to persons either directly or indirectly funded by the foundation.
- Foundation personnel will work hard in recruiting more diverse representation in CTVD.

**Please do not hesitate to send comments and suggestions to [Melvin.Sanicas@gatesfoundation.org](mailto:Melvin.Sanicas@gatesfoundation.org) and to [Willem.Hanekom@gatesfoundation.org](mailto:Willem.Hanekom@gatesfoundation.org).**